Sepracor Lunesta Cancer Risk At Center Of FDA Approvability Debate

Unusually strict eligibility criteria in the only long-term trial supporting Sepracor’s Lunesta NDA complicated FDA’s analysis of carcinogenicity risk, one of the major issues in the review.